News
Reset Health Appoints Alex Nancekievill as Group Chief Technology Officer
The appointment of former Chief Technology Officer at Healthcare Business Solutions further strengthens Reset Health's leadership team as it accelerates platform development and expands its NHS and commercial partnerships
London, United Kingdom. 31 March 2026. Reset Health (“the Company”), the experts in the personalised management of chronic disease, today announces the appointment of Alex Nancekievill as Group Chief Technology Officer (CTO). Alex further strengthens the Company’s technology-enabled, clinically driven model of integrated care as it continues to grow the Reset Health platform and deepens its partnerships with NHS and commercial private partners.
Alex initially joined Reset Health in October 2025 as Technology Advisor. As Group CTO, he will lead Reset Health's technology strategy and R&D, drive the continued development and expansion of the Company's technology portfolio, explore new technology licensing opportunities, and build and lead the broader technology workforce as the Company scales domestically and internationally.
Alex brings more than 25 years of experience building and commercialising technology products across healthcare and regulated industries. He has twice built and led technology businesses through successful acquisitions. Most recently he served on the Board at Healthcare Business Solutions, where he led development of a regulated digital healthcare platform through to its acquisition by AXA Health. Prior to that as a Company Director at Asymptote, he built a regulated biotech digital platform before leading the sale of the business to GE Healthcare. Earlier in his career, Alex spent a decade at ARM, progressing from CPU designer to Chief Information Officer, overseeing a global technology function across nine countries.
Oliver McGuinness, Chief Executive Officer at Reset Health, said: "Reset Health was founded on the belief that successful obesity treatment requires continuous, clinically led care supported by intelligent technology. As we enter an exciting new chapter of growth, having the right technology leadership in place as we increase our investment across R&D and core platform delivery is critical. Alex's experience building and scaling regulated digital health platforms, from deep engineering foundations through to executive leadership, will be instrumental in ensuring our technology keeps step with our clinical ambitions and delivers better outcomes for patients, clinicians and health systems."
Alex joins Reset Health at a pivotal stage of growth as the Company continues to advance its integrated care model for chronic conditions, leading with obesity. Reset Health combines intelligent digital tools with expert clinical leadership to deliver personalised weight management.
Alex Nancekievill, Group Chief Technology Officer at Reset Health, commented: “Reset Health has built a highly differentiated model that brings together clinical expertise and digital innovation to support long-term, sustainable weight management. I am excited to join as Group CTO and work with our clinical and technology teams to further enhance the platform, ensuring we deliver secure, scalable and impactful tools that truly support patients in restoring and maintaining good health.”
ENDS
For media enquiries, contact 5654 & Company
Matthew Neal (+44 7917 800 011)
Charlotte Dawson (+447810 406 284)
Notes to Editors
About Reset Health
Reset Health (www.resethealth.clinic) is a digital health company delivering end-to-end management of chronic conditions by combining its Reset Technology Platform (RTP), with the latest innovative evidence-based clinical care pathways for each chronic condition it treats. Reset’s integrated care model for metabolic health, Roczen (www.roczen.com), is used in conjunction with new anti-obesity medications, GLP-1s and GIPs, to enhance health outcomes of patients with obesity and associated co-morbidities.
Reset Health is regulated by the Care Quality Commission, and Roczen has been evaluated by NICE for delivering multidisciplinary weight-management services and for prescribing and monitoring weight-management medicine. The outcome is a time-limited NICE recommendation for early use within the NHS until March 2028, while further evidence is gathered. Reset Health provides care across the UK, Europe and Malaysia where its integrated care models are available to millions of patients, working with pharma, governments, employers, insurers, private providers and health systems.